Synonyms: PF-00547659 | PF-547659 | SHP647
Compound class:
Antibody
Comment: Ontamalimab (PF-00547659) is a fully human, IgG2, investigational monoclonal antibody targeting mucosal addressin cell adhesion molecule 1 (MADCAM1) [1-2]. It is being evaluated for clinical potential in inflammatory bowel diseases. PF-00547659 was granted FDA orphan drug designation for ulcerative colitis in November 2017.
|
No information available. |
Summary of Clinical Use ![]() |
PF-00547659 has completed Phase 2 clinical trials for ulcerative colitis and Crohn's disease. Results from Phase 2 ulcerative colitis trial NCT01620255 were published by Vermeire et al. in 2017 [3] |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT01620255 | A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis | Phase 2 Interventional | Shire | 3 |